• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

全身性腺病毒基因递送至原位鼠乳腺肿瘤,同时消融凝血因子、血小板和枯否细胞。

Systemic adenoviral gene delivery to orthotopic murine breast tumors with ablation of coagulation factors, thrombocytes and Kupffer cells.

机构信息

Cancer Gene Therapy Group, Molecular Cancer Biology Program and Transplantation Laboratory, Haartman Institute, University of Helsinki, Finland.

出版信息

J Gene Med. 2009 Nov;11(11):966-77. doi: 10.1002/jgm.1373.

DOI:10.1002/jgm.1373
PMID:19670332
Abstract

BACKGROUND

Rapid clearance of adenoviruses from blood by macrophage lineage cells of the liver and spleen, and binding to platelets, hinder their successful systemic use for cancer gene therapy. Vitamin K dependent coagulation factors are important mediators for the adenovirus liver tropism. Here we aim to determine the effects of coagulation factor, thrombocyte and liver macrophage (Kupffer cell) ablation on biodistribution of serotype 5 adenoviruses in mice with orthotopic breast tumors.

METHODS

Prior to intravenous injection of adenoviruses, mice bearing orthotopic breast tumors were pretreated with warfarin to inhibit vitamin K dependent coagulation factor synthesis, an anti-platelet antibody causing thrombocytopenia or an inhibitor of the Kupffer cell scavenger receptor or their combination. Virus availability in blood after injection was determined from blood samples and transgene expression in tissues analyzed 72 hours afterwards with In Vivo Imaging and luciferase assays.

RESULTS

Warfarin pretreatment reduced gene delivery to liver, spleen and lung. Kupffer cell ablation increased persistence of adenoviruses in blood but didn't affect biodistribution significantly. Depletion of Kupffer cells combined with thrombocytopenia doubled the systemic gene delivery of 5/3 chimeric adenovirus to tumors (p < 0.05). Triple ablation of platelets, Kupffer cells and coagulation factors increased the tumor to liver ratio of systemic adenovirus gene delivery by 81% (p < 0.05).

CONCLUSIONS

Depletion of coagulation factors can reduce transduction of liver, spleen and lung. Kupffer cell depletion is the most feasible method of increasing amount adenovirus in systemic blood flow and in combination with ablation of thrombocytes can increase the transduction of adenovirus to tumors.

摘要

背景

肝和脾中的巨噬细胞谱系细胞以及血小板对腺病毒的快速清除和结合,阻碍了其成功用于癌症基因治疗的全身性应用。维生素 K 依赖性凝血因子是腺病毒肝脏趋向性的重要介质。在这里,我们旨在确定凝血因子、血小板和肝巨噬细胞(枯否细胞)耗竭对原位乳腺癌小鼠中血清型 5 腺病毒生物分布的影响。

方法

在静脉注射腺病毒之前,用华法林预处理携带原位乳腺癌的小鼠,以抑制维生素 K 依赖性凝血因子合成、导致血小板减少的抗血小板抗体或枯否细胞清除受体抑制剂或它们的组合。注射后从血液样本中确定病毒在血液中的可用性,并在 72 小时后通过体内成像和荧光素酶测定分析组织中转基因表达。

结果

华法林预处理降低了肝脏、脾脏和肺部的基因传递。枯否细胞耗竭增加了腺病毒在血液中的持续时间,但对生物分布没有显著影响。枯否细胞耗竭与血小板耗竭相结合使 5/3 嵌合腺病毒的全身基因传递增加了一倍(p<0.05)。血小板、枯否细胞和凝血因子的三重耗竭使全身腺病毒基因传递到肿瘤的肿瘤与肝脏比值增加了 81%(p<0.05)。

结论

凝血因子的耗竭可以减少肝脏、脾脏和肺部的转导。枯否细胞耗竭是增加全身血流中腺病毒数量的最可行方法,与血小板耗竭相结合可以增加腺病毒对肿瘤的转导。

相似文献

1
Systemic adenoviral gene delivery to orthotopic murine breast tumors with ablation of coagulation factors, thrombocytes and Kupffer cells.全身性腺病毒基因递送至原位鼠乳腺肿瘤,同时消融凝血因子、血小板和枯否细胞。
J Gene Med. 2009 Nov;11(11):966-77. doi: 10.1002/jgm.1373.
2
Macrophage depletion combined with anticoagulant therapy increases therapeutic window of systemic treatment with oncolytic adenovirus.巨噬细胞清除联合抗凝治疗可增加溶瘤腺病毒全身治疗的治疗窗。
Cancer Res. 2008 Jul 15;68(14):5896-904. doi: 10.1158/0008-5472.CAN-08-0488.
3
A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes.一种用于生成携带一个或两个转基因的溶瘤腺病毒载体的简化系统。
Cancer Gene Ther. 2008 Mar;15(3):173-82. doi: 10.1038/sj.cgt.7701105. Epub 2007 Dec 21.
4
Functional interactions of antiapoptotic proteins and tumor necrosis factor in the context of a replication-competent adenovirus.在具有复制能力的腺病毒背景下抗凋亡蛋白与肿瘤坏死因子的功能相互作用。
Gene Ther. 2005 Sep;12(17):1333-46. doi: 10.1038/sj.gt.3302555.
5
Concurrent delivery of GM-CSF and endostatin genes by a single adenoviral vector provides a synergistic effect on the treatment of orthotopic liver tumors.通过单一腺病毒载体同时递送GM-CSF和内皮抑素基因对原位肝肿瘤的治疗具有协同作用。
J Gene Med. 2003 May;5(5):386-98. doi: 10.1002/jgm.376.
6
Triple-targeted oncolytic adenoviruses featuring the cox2 promoter, E1A transcomplementation, and serotype chimerism for enhanced selectivity for ovarian cancer cells.具有cox2启动子、E1A反式互补和血清型嵌合的三重靶向溶瘤腺病毒,以增强对卵巢癌细胞的选择性。
Mol Ther. 2006 Aug;14(2):164-74. doi: 10.1016/j.ymthe.2006.01.010. Epub 2006 Mar 31.
7
Luciferase imaging for evaluation of oncolytic adenovirus replication in vivo.用于评估溶瘤腺病毒体内复制的荧光素酶成像
Gene Ther. 2007 Jun;14(11):902-11. doi: 10.1038/sj.gt.3302949. Epub 2007 Mar 22.
8
Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus.双调控溶瘤腺病毒对肝细胞癌具有增强的安全性并保留抗肿瘤疗效。
Clin Cancer Res. 2006 Nov 1;12(21):6523-31. doi: 10.1158/1078-0432.CCR-06-1491.
9
Growth inhibition of human multiple myeloma cells by an oncolytic adenovirus carrying the CD40 ligand transgene.携带CD40配体转基因的溶瘤腺病毒对人多发性骨髓瘤细胞的生长抑制作用
Clin Cancer Res. 2009 Aug 1;15(15):4847-56. doi: 10.1158/1078-0432.CCR-09-0451. Epub 2009 Jul 21.
10
A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo.一种survivin介导的溶瘤腺病毒可诱导肺癌细胞发生非凋亡性细胞死亡,并在体内显示出抗肿瘤潜力。
J Gene Med. 2006 Oct;8(10):1232-42. doi: 10.1002/jgm.953.

引用本文的文献

1
Tutorial: design, production and testing of oncolytic viruses for cancer immunotherapy.教程:用于癌症免疫疗法的溶瘤病毒的设计、生产和测试。
Nat Protoc. 2024 Sep;19(9):2540-2570. doi: 10.1038/s41596-024-00985-1. Epub 2024 May 20.
2
4-Week repeated dose rat GLP toxicity study of oncolytic ECHO-7 virus Rigvir administered intramuscularly with a 4-week recovery period.溶瘤ECHO-7病毒Rigvir经肌肉注射给药、有4周恢复期的4周重复剂量大鼠GLP毒性研究。
Toxicol Rep. 2021 Jan 19;8:230-238. doi: 10.1016/j.toxrep.2021.01.009. eCollection 2021.
3
How Computational Chemistry and Drug Delivery Techniques Can Support the Development of New Anticancer Drugs.
计算化学和药物输送技术如何支持新型抗癌药物的开发。
Molecules. 2020 Apr 10;25(7):1756. doi: 10.3390/molecules25071756.
4
Designing and building oncolytic viruses.设计和构建溶瘤病毒。
Future Virol. 2017 Apr;12(4):193-213. doi: 10.2217/fvl-2016-0129. Epub 2017 Mar 31.
5
Adenoviral vector with shield and adapter increases tumor specificity and escapes liver and immune control.带有屏蔽和适配子的腺病毒载体增加了肿瘤的特异性,并逃避了肝脏和免疫的控制。
Nat Commun. 2018 Jan 31;9(1):450. doi: 10.1038/s41467-017-02707-6.
6
Toxicological and bio-distribution profile of a GM-CSF-expressing, double-targeted, chimeric oncolytic adenovirus ONCOS-102 - Support for clinical studies on advanced cancer treatment.表达GM-CSF的双靶点嵌合溶瘤腺病毒ONCOS-102的毒理学和生物分布概况——对晚期癌症治疗临床研究的支持
PLoS One. 2017 Aug 10;12(8):e0182715. doi: 10.1371/journal.pone.0182715. eCollection 2017.
7
Oncolytic Adenoviruses in Cancer Treatment.溶瘤腺病毒在癌症治疗中的应用
Biomedicines. 2014 Feb 21;2(1):36-49. doi: 10.3390/biomedicines2010036.
8
Promising oncolytic agents for metastatic breast cancer treatment.用于转移性乳腺癌治疗的有前景的溶瘤剂。
Oncolytic Virother. 2015 Jun 3;4:63-73. doi: 10.2147/OV.S63045. eCollection 2015.
9
Overcoming tumor resistance by heterologous adeno-poxvirus combination therapy.通过异源腺病毒联合治疗克服肿瘤耐药性。
Mol Ther Oncolytics. 2015 Jan 7;1:14006. doi: 10.1038/mto.2014.6. eCollection 2015.
10
Retargeting of gene expression using endothelium specific hexon modified adenoviral vector.利用内皮细胞特异性六邻体修饰的腺病毒载体进行基因表达的重定向。
Virology. 2013 Dec;447(1-2):312-25. doi: 10.1016/j.virol.2013.09.020. Epub 2013 Oct 15.